MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Should be stored at 2-8C. May remove for a single period of up to 3 months during which it must be stored at a temperature not above 25C.

Provenance

Compatibility recommendation derived from Orfadin 10mg capsules (Swedish Orphan Biovitrum Ltd).

Stability Notes

Should be stored at 2-8C. May remove for a single period of up to 3 months during which it must be stored at a temperature not above 25C.

Provenance

Compatibility recommendation derived from Orfadin 2mg capsules (Swedish Orphan Biovitrum Ltd).

Stability Notes

Should be stored at 2-8C. May remove for a single period of up to 3 months during which it must be stored at a temperature not above 25C.

Provenance

Compatibility recommendation derived from Orfadin 5mg capsules (Swedish Orphan Biovitrum Ltd).

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Nitrazepam 5mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Nitrazepam 5mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Nitrazepam 5mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Nitrazepam 5mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Nitrazepam 5mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Nitrazepam 5mg tablets (Accord Healthcare Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.